5741359
Last Update Posted: 2024-01-08
Recruiting
All Genders accepted | 18 Years + |
18 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects. Based on the "3 + 3" dose escalation design principle, subjects will be divided into 3 groups from low dose to high dose in sequence (Group A; Group B; Group C. Additional subjects will be enrolled into the RP2D group to ensure that 6-9 efficacy-evaluable subjects are available in the RP2D group before entering the phase II study.
Eligibility
Relevant conditions:
Non-hodgkin Lymphoma,B Cell
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Wei Li, PhD
wli@brlmed.com
18621670308
Data sourced from ClinicalTrials.gov